(Post-pandemic Era)-Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment Research Report 2024

Report ID: 875117 | Published Date: Jan 2026 | No. of Page: 80 | Base Year: 2025 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

Table of Contents

Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment Research Report 2021
1. Research Scope
2. Market Overview
    2.1 Product Introduction, Application, Picture
    2.2 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market by Value
      2.2.1 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
      2.2.2 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market by Value (%)
    2.3 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market by Production
      2.3.1 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Production by Type
      2.3.2 Global The Glucagon Like Peptide-1 (GLP-1) Agonists Market by Production (%)

3. The Major Driver of The Glucagon Like Peptide-1 (GLP-1) Agonists Industry
    3.1 Historical & Forecast Global The Glucagon Like Peptide-1 (GLP-1) Agonists Demand
    3.2 Largest Application for The Glucagon Like Peptide-1 (GLP-1) Agonists (2017-2027)
    3.3 The Major Downstream Company in China Market 2021

4. Global and Regional The Glucagon Like Peptide-1 (GLP-1) Agonists Market
    4.1 Regional Market Size in Terms of Production & Demand (2021)
    4.2 Regional Market Share in Terms of Revenue (2019-2027) 
    4.3 Concentration Ratio (CR5& CR10) of The Glucagon Like Peptide-1 (GLP-1) Agonists Market
    4.4 Mergers & Acquisitions, Expansion Plans

5. US The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    5.1 Current and Estimated Production Breakdown by Type
    5.2 Current and Estimated Demand Breakdown by Type
    5.3 Current and Estimated Demand Breakdown by Application
    5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

6. Europe The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    6.1 Current and Estimated Production Breakdown by Type
    6.2 Current and Estimated Demand Breakdown by Type
    6.3 Current and Estimated Demand Breakdown by Application
    6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

7. China The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    7.1 Current and Estimated Production Breakdown by Type
    7.2 Current and Estimated Demand Breakdown by Type
    7.3 Current and Estimated Demand Breakdown by Application
    7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

8. Japan The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    8.1 Current and Estimated Production Breakdown by Type
    8.2 Current and Estimated Demand Breakdown by Type
    8.3 Current and Estimated Demand Breakdown by Application
    8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

9. India The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    9.1 Current and Estimated Production Breakdown by Type
    9.2 Current and Estimated Demand Breakdown by Type
    9.3 Current and Estimated Demand Breakdown by Application
    9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

10. Korea The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    10.1 Current and Estimated Production Breakdown by Type
    10.2 Current and Estimated Demand Breakdown by Type
    10.3 Current and Estimated Demand Breakdown by Application
    10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

11. Southeast Asia The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    11.1 Current and Estimated Production Breakdown by Type
    11.2 Current and Estimated Demand Breakdown by Type
    11.3 Current and Estimated Demand Breakdown by Application
    11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
    11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

12. Global The Glucagon Like Peptide-1 (GLP-1) Agonists Average Price Trend
    12.1 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in US (2017-2021)
    12.2 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Europe (2017-2021)
    12.3 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in China (2017-2021)
    12.4 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Japan (2017-2021)
    12.5 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in India (2017-2021)
    12.6 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Korea (2017-2021)
    12.7 Market Price for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Southeast Asia (2017-2021)

13. Industrial Chain (Impact of COVID-19)
    13.1 The Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
    13.2 Downstream
    13.3 Impact of COVID-19
    13.4 Technology Trends of The Glucagon Like Peptide-1 (GLP-1) Agonists

14. The Glucagon Like Peptide-1 (GLP-1) Agonists Competitive Landscape
     14.1 Novo Nordisk
        14.1.1 Novo Nordisk Company Profiles
        14.1.2 Novo Nordisk Product Introduction
        14.1.3 Novo Nordisk The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.1.4 Strategic initiatives
     14.2 GSK
        14.2.1 GSK Company Profiles
        14.2.2 GSK Product Introduction
        14.2.3 GSK The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.2.4 Strategic initiatives
     14.3 AstraZeneca
        14.3.1 AstraZeneca Company Profiles
        14.3.2 AstraZeneca Product Introduction
        14.3.3 AstraZeneca The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.3.4 Strategic initiatives
     14.4 Amylin
        14.4.1 Amylin Company Profiles
        14.4.2 Amylin Product Introduction
        14.4.3 Amylin The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.4.4 Strategic initiatives
     14.5 Eli Lilly
        14.5.1 Eli Lilly Company Profiles
        14.5.2 Eli Lilly Product Introduction
        14.5.3 Eli Lilly The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.5.4 Strategic initiatives
     14.6 Bristol-Myers Squibb
        14.6.1 Bristol-Myers Squibb Company Profiles
        14.6.2 Bristol-Myers Squibb Product Introduction
        14.6.3 Bristol-Myers Squibb The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.6.4 Strategic initiatives
     14.7 Sanofi
        14.7.1 Sanofi Company Profiles
        14.7.2 Sanofi Product Introduction
        14.7.3 Sanofi The Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue (2017-2021)
        14.7.4 Strategic initiatives
15. Conclusion


List of Tables and Figures

    Figure 1. Total Demand by Application of The Glucagon Like Peptide-1 (GLP-1) Agonists Industry (Volume)
    Figure 2. The Glucagon Like Peptide-1 (GLP-1) Agonists Production & Demand by Regions in 2021
    Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
    Figure 4. The Top 10 and 5 Players Market Share by The Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2021
    Figure 5. US The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 6. Production Breakdown by Type (%)
    Figure 7. Demand Breakdown by Type (%)
    Figure 8. Demand Breakdown by Application (%)
    Figure 9. Revenue Breakdown by Type (%)
    Figure 10. Revenue Breakdown by Application (%)
    Figure 11. Europe The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 12. Production Breakdown by Type (%)
    Figure 13. Demand Breakdown by Type (%)
    Figure 14. Demand Breakdown by Application (%)
    Figure 15. Revenue Breakdown by Type (%)
    Figure 16. Revenue Breakdown by Application (%)
    Figure 17. China The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 18. Production Breakdown by Type (%)
    Figure 19. Demand Breakdown by Type (%)
    Figure 20. Demand Breakdown by Application (%)
    Figure 21. Current and Estimated Revenue Breakdown by Type
    Figure 22. Revenue Breakdown by Type (%)
    Figure 23. Revenue Breakdown by Application (%)
    Figure 24. Japan The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 25. Production Breakdown by Type (%)
    Figure 26. Demand Breakdown by Type (%)
    Figure 27. Demand Breakdown by Application (%)
    Figure 28. Revenue Breakdown by Type (%)
    Figure 29. Revenue Breakdown by Application (%)
    Figure 30. India The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 31. Production Breakdown by Type (%)
    Figure 32. Demand Breakdown by Type (%)
    Figure 33. Demand Breakdown by Application (%)
    Figure 34. Revenue Breakdown by Type (%)
    Figure 35. Revenue Breakdown by Application (%)
    Figure 36. Korea The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 37. Production Breakdown by Type (%)
    Figure 38. Demand Breakdown by Type (%)
    Figure 39. Demand Breakdown by Application (%)
    Figure 40. Revenue Breakdown by Type (%)
    Figure 41. Revenue Breakdown by Application (%)
    Figure 42. Southeast Asia The Glucagon Like Peptide-1 (GLP-1) Agonists Production, Demand (2017-2027)
    Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
    Figure 44. Production Breakdown by Type (%)
    Figure 45. Demand Breakdown by Type (%)
    Figure 46. Revenue Breakdown by Type (%)
    Figure 47. Revenue Breakdown by Application (%)
    Figure 48. Industrial Chain
    Table 1. Top Manufacturers and Market Segmentation
    Table 2. Product Introduction, Application, Picture
    Table 3. The Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, by Type (Million USD) (2017-2027)
    Table 4. The Glucagon Like Peptide-1 (GLP-1) Agonists Production, by Type (K Unit) (2017-2027)
    Table 5. The Glucagon Like Peptide-1 (GLP-1) Agonists Demand (K Unit) by Application (2017-2027)
    Table 6. The Glucagon Like Peptide-1 (GLP-1) Agonists Demand (Million USD) by Application (2017-2027)
    Table 7. The Major Downstream Company in China
    Table 8. Regional Market Share in Terms of Production & Demand (2021)
    Table 9. Regional Market Share in Terms of Revenue (2021&2027)
    Table 10. Ranking of Global Top The Glucagon Like Peptide-1 (GLP-1) Agonists Companies by Revenue, Concentration Ratio in 2021
    Table 11. Mergers & Acquisitions, Expansion Plans
    Table 12. US The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 16. Current and Estimated Revenue Breakdown by Type
    Table 17. Current and Estimated Revenue Breakdown by Application
    Table 18. Europe The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 22. Current and Estimated Revenue Breakdown by Type
    Table 23. Current and Estimated Revenue Breakdown by Application
    Table 24. China The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 25. Table Current and Estimated Production Breakdown by Type
    Table 26. Current and Estimated Demand Breakdown by Type
    Table 27. Current and Estimated Demand Breakdown by Application
    Table 28. Current and Estimated Revenue Breakdown by Application
    Table 29. Japan The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 33. Current and Estimated Revenue Breakdown by Type
    Table 34. Current and Estimated Revenue Breakdown by Application
    Table 35. India The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 39. Current and Estimated Revenue Breakdown by Type
    Table 40. Current and Estimated Revenue Breakdown by Application
    Table 41. Korea The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
    Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 45. Current and Estimated Revenue Breakdown by Type
    Table 46. Current and Estimated Revenue Breakdown by Application
    Table 47. Southeast Asia The Glucagon Like Peptide-1 (GLP-1) Agonists Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
    Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
    Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
    Table 50. Current and Estimated Revenue Breakdown by Type
    Table 51. Current and Estimated Revenue Breakdown by Application
    Table 52. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in US (2017-2021)
    Table 53. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Europe (2017-2021)
    Table 54. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in China (2017-2021)
    Table 55. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Japan (2017-2021)
    Table 56. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in India (2017-2021)
    Table 57. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Korea (2017-2021)
    Table 58. Market Price (USD/Unit) for Each Type of The Glucagon Like Peptide-1 (GLP-1) Agonists in Southeast Asia (2017-2021)
    Table 59. Key Downstream Customer in Each Application Field
    Table 60. Novo Nordisk Profiles
    Table 61. Novo Nordisk The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 62. Novo Nordisk The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 63. Novo Nordisk Strategic initiatives
    Table 64. GSK Profiles
    Table 65. GSK The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 66. GSK The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 67. GSK Strategic initiatives
    Table 68. AstraZeneca Profiles
    Table 69. AstraZeneca The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 70. AstraZeneca The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 71. AstraZeneca Strategic initiatives
    Table 72. Amylin Profiles
    Table 73. Amylin The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 74. Amylin The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 75. Amylin Strategic initiatives
    Table 76. Eli Lilly Profiles
    Table 77. Eli Lilly The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 78. Eli Lilly The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 79. Eli Lilly Strategic initiatives
    Table 80. Bristol-Myers Squibb Profiles
    Table 81. Bristol-Myers Squibb The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 82. Bristol-Myers Squibb The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
    Table 83. Bristol-Myers Squibb Strategic initiatives
    Table 84. Sanofi Profiles
    Table 85. Sanofi The Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
    Table 86. Sanofi The Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Unit), Revenue (Million USD) (2017-2021)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
-Global The Glucagon Like Peptide-1 Agonists Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
-Global The Glucagon Like Peptide-1 Agonists Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
-Global The Glucagon Like Peptide-1 Agonists Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports